Cargando…

Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma

PURPOSE: We previously investigated the efficacy and safety of adding 0.1% brimonidine (Brim) or 0.5% timolol (Tim) to prostaglandin analogue (PGA) monotherapy to treat patients with normal-tension glaucoma (NTG) with intraocular pressure (IOP) of ≤16 mmHg. Herein, we describe an additional post-hoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshikawa, Keiji, Mizoue, Shiro, Nitta, Koji, Onishi, Hiroshi, Ikeda, Masaharu, Mizuno, Akemi, Kawazoe, Kaori, Tamada, Yoshiyuki, Takeda, Ryuji, Matsumoto, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274234/
https://www.ncbi.nlm.nih.gov/pubmed/34262247
http://dx.doi.org/10.2147/OPTH.S318392
_version_ 1783721522382241792
author Yoshikawa, Keiji
Mizoue, Shiro
Nitta, Koji
Onishi, Hiroshi
Ikeda, Masaharu
Mizuno, Akemi
Kawazoe, Kaori
Tamada, Yoshiyuki
Takeda, Ryuji
Matsumoto, Shun
author_facet Yoshikawa, Keiji
Mizoue, Shiro
Nitta, Koji
Onishi, Hiroshi
Ikeda, Masaharu
Mizuno, Akemi
Kawazoe, Kaori
Tamada, Yoshiyuki
Takeda, Ryuji
Matsumoto, Shun
author_sort Yoshikawa, Keiji
collection PubMed
description PURPOSE: We previously investigated the efficacy and safety of adding 0.1% brimonidine (Brim) or 0.5% timolol (Tim) to prostaglandin analogue (PGA) monotherapy to treat patients with normal-tension glaucoma (NTG) with intraocular pressure (IOP) of ≤16 mmHg. Herein, we describe an additional post-hoc stratifying analysis of the possible differences in the effect of IOP-lowering and pulse rate (PR) after adjunctive Brim or Tim to PGA. PATIENTS AND METHODS: This study included 128 subjects. Patients with NTG treated with PGA were stratified based on their baseline IOP. The changes in IOP from baseline and the effect of patient factors on IOP changes were investigated. Patients were stratified by age for investigation of their PR and blood pressure (BP). The change and the effect of patient factors on PR and BP were investigated. RESULTS: After stratification analysis, in 52 eyes treated with Brim and 61 eyes with Tim with baseline IOP 12 ≤ IOP ≤ 16 mmHg, both eye drops lowered IOP significantly (P < 0.0001), and the IOP-lowering efficacy of Brim was non-inferior to that of Tim. However, in 9 Brim- and 6 Tim-treated eyes with baseline IOP of <12 mmHg, no statistically significant decrease in IOP was evident with either eye drop. In the Tim group, PR decreased significantly (P < 0.05) after stratification by age. CONCLUSION: The IOP-lowering efficacy of Brim was non-inferior to that of Tim after stratification by baseline IOP (12 ≤ IOP ≤ 16 mmHg). The discrepancy in the IOP-lowering effects of Brim and Tim observed in the previous study was thought to be related to enrolled subjects with low baseline IOP. PR decreased significantly in the Tim group even after age stratification. PR should be considered when selecting β-blockers for glaucoma treatment.
format Online
Article
Text
id pubmed-8274234
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-82742342021-07-13 Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma Yoshikawa, Keiji Mizoue, Shiro Nitta, Koji Onishi, Hiroshi Ikeda, Masaharu Mizuno, Akemi Kawazoe, Kaori Tamada, Yoshiyuki Takeda, Ryuji Matsumoto, Shun Clin Ophthalmol Original Research PURPOSE: We previously investigated the efficacy and safety of adding 0.1% brimonidine (Brim) or 0.5% timolol (Tim) to prostaglandin analogue (PGA) monotherapy to treat patients with normal-tension glaucoma (NTG) with intraocular pressure (IOP) of ≤16 mmHg. Herein, we describe an additional post-hoc stratifying analysis of the possible differences in the effect of IOP-lowering and pulse rate (PR) after adjunctive Brim or Tim to PGA. PATIENTS AND METHODS: This study included 128 subjects. Patients with NTG treated with PGA were stratified based on their baseline IOP. The changes in IOP from baseline and the effect of patient factors on IOP changes were investigated. Patients were stratified by age for investigation of their PR and blood pressure (BP). The change and the effect of patient factors on PR and BP were investigated. RESULTS: After stratification analysis, in 52 eyes treated with Brim and 61 eyes with Tim with baseline IOP 12 ≤ IOP ≤ 16 mmHg, both eye drops lowered IOP significantly (P < 0.0001), and the IOP-lowering efficacy of Brim was non-inferior to that of Tim. However, in 9 Brim- and 6 Tim-treated eyes with baseline IOP of <12 mmHg, no statistically significant decrease in IOP was evident with either eye drop. In the Tim group, PR decreased significantly (P < 0.05) after stratification by age. CONCLUSION: The IOP-lowering efficacy of Brim was non-inferior to that of Tim after stratification by baseline IOP (12 ≤ IOP ≤ 16 mmHg). The discrepancy in the IOP-lowering effects of Brim and Tim observed in the previous study was thought to be related to enrolled subjects with low baseline IOP. PR decreased significantly in the Tim group even after age stratification. PR should be considered when selecting β-blockers for glaucoma treatment. Dove 2021-07-06 /pmc/articles/PMC8274234/ /pubmed/34262247 http://dx.doi.org/10.2147/OPTH.S318392 Text en © 2021 Yoshikawa et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yoshikawa, Keiji
Mizoue, Shiro
Nitta, Koji
Onishi, Hiroshi
Ikeda, Masaharu
Mizuno, Akemi
Kawazoe, Kaori
Tamada, Yoshiyuki
Takeda, Ryuji
Matsumoto, Shun
Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma
title Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma
title_full Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma
title_fullStr Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma
title_full_unstemmed Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma
title_short Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma
title_sort stratification-based investigation of adjunctive brimonidine or timolol to a prostaglandin analogue in japanese patients with normal-tension glaucoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274234/
https://www.ncbi.nlm.nih.gov/pubmed/34262247
http://dx.doi.org/10.2147/OPTH.S318392
work_keys_str_mv AT yoshikawakeiji stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma
AT mizoueshiro stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma
AT nittakoji stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma
AT onishihiroshi stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma
AT ikedamasaharu stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma
AT mizunoakemi stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma
AT kawazoekaori stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma
AT tamadayoshiyuki stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma
AT takedaryuji stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma
AT matsumotoshun stratificationbasedinvestigationofadjunctivebrimonidineortimololtoaprostaglandinanalogueinjapanesepatientswithnormaltensionglaucoma